Serum Electrolytes and Contrast-Induced Nephropathy in Acute Ischemic Stroke Patients Undergoing Endovascular Treatment

NCT07546448 | Not Yet Recruiting

• 1 other identifier: 27.012.2026-37
• Study Type: observational
• Target: 250
• Locations: 1 country
• Sites: 1

Brief Summary

This study aims to evaluate the relationship between serum electrolyte levels and the development of contrast-induced acute kidney injury (CI-AKI) in patients with acute ischemic stroke undergoing endovascular therapy (EVT). Contrast-induced nephropathy remains a significant complication associated with endovascular procedures and is linked to increased morbidity and mortality. While several risk factors have been identified, the role of serum electrolyte imbalances in the development of CI-AKI has not been fully elucidated. In this retrospective cohort study, patients treated with EVT between 2018 and 2026 will be analyzed. Patients will be classified based on the presence or absence of CI-AKI according to changes in serum creatinine levels. Demographic data, comorbidities, laboratory parameters-including serum electrolytes-and procedural variables will be compared between groups. The primary objective is to determine whether serum electrolyte levels are associated with the risk of CI-AKI. Secondary objectives include evaluating 90-day mortality and dialysis dependency in patients who develop CI-AKI.

Conditions

Acute Ischemic Stroke; Contrast-induced Nephropathy; Acute Kidney Injury

Keywords

Acute Ischemic Stroke; Contrast-Induced Acute Kidney Injury

Outcome Measures

Primary Outcomes (1)

• Incidence of contrast-induced acute kidney injury (CI-AKI)

  CI-AKI will be identified based on post-procedural serum creatinine changes after contrast exposure according to established diagnostic criteria.

  Within 48-72 hours after contrast exposure

Secondary Outcomes (7)

• 90-day mortality

  Within 90 days after endovascular therapy

• Dialysis dependency in patients with CI-AKI

  Within 90 days after endovascular therapy

• Change in serum creatinine

  Baseline to 48-72 hours after endovascular therapy

• Association between serum electrolyte levels and CI-AKI

  Baseline (pre-procedural measurements)

• Length of hospital stay

  Within 90 days after endovascular therapy

Study Arms (2)

CI-AKI Group

Patients who developed contrast-induced acute kidney injury (CI-AKI) following endovascular therapy for acute ischemic stroke, defined by an increase in serum creatinine levels according to established diagnostic criteria after contrast exposure. These patients were identified based on post-procedural renal function changes and included in the analysis to evaluate clinical, laboratory, and procedural factors associated with CI-AKI development.

Other: No intervention (observational cohort study)

Non-CI-AKI Group

Patients who underwent endovascular therapy for acute ischemic stroke but did not develop contrast-induced acute kidney injury based on post-procedural serum creatinine measurements.

Other: No intervention (observational cohort study)

Interventions

No intervention (observational cohort study) OTHER

No experimental or therapeutic intervention was assigned. This observational retrospective cohort study evaluated patients undergoing endovascular therapy for acute ischemic stroke, who were subsequently categorized based on the presence or absence of contrast-induced acute kidney injury (CI-AKI). The study analyzed demographic, clinical, laboratory (including serum electrolyte levels) and procedural variables to identify potential risk factors associated with CI-AKI development.

CI-AKI Group; Non-CI-AKI Group

Eligibility Criteria

• Age: 18 Years - 100 Years
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

This study includes adult patients (≥18 years) with acute ischemic stroke who underwent endovascular therapy at a tertiary referral center between 2018 and 2026. Patients with sufficient clinical and laboratory data, including pre- and post-procedural serum creatinine measurements, will be eligible for inclusion. The cohort reflects a real-world population of patients undergoing EVT, encompassing a wide range of demographic and clinical characteristics, including common vascular comorbidities. Patients will be stratified according to the development of contrast-induced acute kidney injury (CI-AKI) for comparative analyses.

You may qualify if:

• Adults aged 18 years or older
• Patients diagnosed with acute ischemic stroke
• Patients who underwent endovascular therapy for acute ischemic stroke between 2018 and 2026
• Patients with a baseline NIHSS score of 6 or higher
• Patients who received iodinated contrast medium during the endovascular procedure
• Patients managed under general anesthesia
• Patients with available pre-procedural and post-procedural serum creatinine measurements sufficient to assess contrast-induced acute kidney injury

You may not qualify if:

• Age younger than 18 years
• Pre-existing acute kidney injury or chronic kidney disease meeting KDIGO stage 1-3 before endovascular therapy
• APACHE score greater than 25 at the time of the procedure
• Known allergy or hypersensitivity to iodinated contrast media
• Exposure to iodinated contrast media within the previous 2 weeks
• Use of nephrotoxic medications within the previous 2 weeks
• History of myocardial infarction or previous stroke
• Use of vasopressor/inotropic agents such as dopamine at the time of the procedure
• Systemic steroid use at the time of the procedure
• Incomplete medical records or missing laboratory data required for evaluation of CI-AKI

Sponsors & Collaborators

• Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital: lead

Study Sites (1)

Fatma Acil

Diyarbakır, Outside of the US, 21070, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Ischemic Stroke; Acute Kidney Injury

Condition Hierarchy (Ancestors)

Stroke; Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases; Renal Insufficiency; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases

Central Study Contacts

Fatma Acil, M.D.

CONTACT

+905337225225; acilfatma@gmail.com

Abdulkadir Yektaş, Prof.Dr.

CONTACT

+905053881884; akyektas722000@yahoo.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: April 2, 2026
• First Posted: April 22, 2026
• Study Start: April 20, 2026
• Primary Completion (Estimated): May 10, 2026
• Study Completion (Estimated): May 10, 2026
• Last Updated: April 22, 2026

Record last verified: 2026-04

Locations

TU (1)